DUBLIN, Ireland and MELBOURNE, Australia, Feb. 5, 2015 (GLOBE NEWSWIRE) -- Veterinary biologic therapy developer Nexvet Biopharma (Nasdaq:NVET) today announced the pricing of its initial public offering of 4,000,000 ordinary shares at a price to the public of $10.00 per share. The shares are expected to begin trading on the NASDAQ Global Market on February 5, 2015 under the ticker symbol "NVET." All of the ordinary shares are being offered by Nexvet. In addition, Nexvet has granted the underwriters a 30-day option to purchase up to an additional 600,000 ordinary shares.
BofA Merrill Lynch and Cowen and Company are acting as joint lead book-running managers for the offering. Piper Jaffray and JMP Securities are acting as co-managers.
A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission. The offering is being made only by means of a written prospectus forming part of the effective registration statement. Copies of the final prospectus related to the offering may be obtained, when available, from BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attention: Prospectus Department, e-mail: dg.prospectus_requests@baml.com, or from Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717 or by calling 631-274-2806, or by faxing 631-254-7140.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful.